China's medical products administrator granted Jiangsu Hengrui Medicine (SHA:600276) marketing authorization for its emmacitinib sulfate tablets for severe alopecia areata or hair loss in adults.
During clinical trials conducted in June, participants reported good safety and efficacy of the drug, according to a Thursday filing with the Shanghai Stock Exchange.
Price (RMB): ¥45.00, Change: ¥+0.49, Percent Change: +1.10%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments